Precision Medication Therapy Strategy In Crohn's Disease: Financial Advantages Overview In this study, the cost-effectiveness of precision-guided dosing (PGD) of infliximab (IFX) for patients with Crohn's disease (CD) who lose response to biologics was evaluated in comparison to two other dose intensification strategies (DIS). A hybrid model combining Markov and decision tree elements
Tag: Therapeutic drug monitoring
